$CBST Cantor Raises Cubist Pharmaceuticals Price Target In-Line With Merck Offer http://www.smarteranalyst.com/2014/12/11/cantor-raises-cubist-pharmaceuticals-price-target-in-line-with-merck-offer/

CBST and MRK situation is very strange. I wonder if the deal goes through?

$CBST Wedbush Comments On Cubist Pharmaceuticals Following Patent Setback http://www.smarteranalyst.com/2014/12/10/wedbush-comments-on-cubist-pharmaceuticals-following-patent-setback/

Sold over $100. Didn't want them to bring her back down. Forget that took my profit lol.

$CBST Wedbush Raises Cubist Price Target On The Back Of Merck Acquisition Value http://www.smarteranalyst.com/2014/12/09/wedbush-raises-cubist-price-target-on-the-back-of-merck-acquisition-value/

Already made my money here hopped out over $100. Happy camper.

$CBST Oppenheimer Comments On Cubist Pharmaceuticals As Merck Is Nearing An $8B Takeover http://www.smarteranalyst.com/2014/12/08/oppenheimer-reiterates-outperform-on-cubist-pharmaceuticals-shares-sees-18-downside-for-the-stock/

VOLUME

$CBST Cantor Raises Cubist Pharmaceuticals Price Target Following Merck Acquisition http://www.smarteranalyst.com/2014/12/08/cantor-maintains-hold-on-cubist-pharmaceuticals-shares-sees-11-downside-for-the-stock/

Any idea what happens with the $1.0+ shareholder bonus on achieving sales goal of tetizold TR-701 (supposed to kick in 2017) with Merck acquisition of cubist. Does the timetable accelerate for original shareholders of trius?

Congratulations Cubist!!!
When is PPHMs turn?
wook

Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash

Acquisition Augments Merck’s Strong Foundation and Opportunity for Growth in Hospital Acute Care Market

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days.

Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also include $1.1 billion in net debt (based on projected cash balances) and other considerations for a total transaction value of approximately $9.5 billion.

“Cubist is a global leader in antibiotics and has built a strong portfolio of both marketed and late-stage pipeline medicines,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “Combining this expertise with Merck’s strong capabilities and global reach will enable us to create a stronger position in hospital acute care while addressing critical areas of unmet medical need, such as antibiotic resistance.”

“Combining with Merck is an exciting opportunity to accelerate Cubist’s established leadership in antibiotics and deliver significant, certain and immediate value to shareholders,” said Michael Bonney, chief executive officer, Cubist. “We have a deep respect for Merck, and it is clear that they share our commitment to addressing the growing, global problem we are facing in combating antibiotic-resistant bacteria. Under Merck’s robust commercial platform, global reach and scientific expertise, we believe Cubist's programs can thrive. We’re proud of the company that our team has built and are confident that Cubist's important mission and focus on significant unmet medical needs will continue.”

For more than 20 years, Cubist has been committed to global public health through the discovery, development and supply of antibiotics to treat serious and potentially life-threatening infections caused by a broad range of increasingly drug-resistant bacteria. Cubist’s antibiotic CUBICIN®, the only approved once-a-day therapy for both S. aureus bacteremia and complicated skin and skin structure infections (cSSSI), has been used to treat more than two million patients and continues to be an important therapy in the acute care environment. Cubist’s in-line and late-stage pipeline of anti-infective medicines, including ZERBAXA™ which is pending approval from the U.S. Food and Drug Administration, will enhance Merck’s hospital acute care business in a variety of therapeutic areas, including Gram-positive and Gram-negative multi-drug resistant infections.

The acquisition of Cubist creates strong fundamental value with return on capital in excess of Merck's hurdle rate within a few years of closing. Merck expects the acquisition to add more than $1 billion of revenue to its 2015 base. While the transaction will be neutral to non-GAAP EPS in 2015, Merck expects it to be significantly accretive to non-GAAP EPS in 2016 and beyond. The acquisition will be accretive to both Merck’s sales and earnings growth.

Cubist complements Merck’s strategy and the global initiative Merck launched last year, particularly in the area of sharpening its commercial focus on key therapeutic areas that have the potential to deliver the greatest return on investment. With the company’s long-standing leadership in anti-infectives as well as its customer-focused operating model, Merck identified the hospital acute care segment as one of the company’s key priority areas in which it believes it can have the greatest impact in addressing significant unmet medical needs while delivering the greatest value to customers and society.

Merck strategically focused on acute care within the larger hospital setting as a top priority because of the significant unmet need and the unique opportunities for Merck to improve patient care and manage costs in this setting with its in-line portfolio, promising pipeline and its customer capabilities.

Hospitals are a central hub for healthcare delivery around the world and currently represent 25 percent of overall healthcare spend. Merck believes now is an optimal time to significantly grow its hospital acute care presence because of the positive regulatory and reimbursement trends in the hospital setting and the increasingly important role that hospitals are expected to provide in healthcare overall.

For the first three quarters of 2014 compared to 2013, Merck’s hospital acute care portfolio grew by more than 10 percent, excluding the impact of foreign exchange. Key products in Merck’s hospital acute care portfolio include several antibiotics and antifungals, as well as BRIDION® (sugammadex), which is marketed outside the United States and is currently under regulatory review in the United States. In addition, Merck has continued to invest in its hospital acute care pipeline and has several candidates, including actoxumab/bezlotoxumab (MK-3415A), an investigational combination of therapeutic antibodies targeting two C.difficile pathogenic toxins (A and B), which is being evaluated in clinical trials for the prevention of recurrence of C.difficile infection; and relebactam (MK-7655), an investigational class A and C beta-lactamase inhibitor being evaluated in clinical trials for the treatment of severe bacterial infections.

Under the terms of the agreement, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Cubist Pharmaceuticals, Inc. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Cubist’s outstanding shares (assuming the exercise of all options), the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Upon the completion of the tender offer, Merck will acquire all remaining shares through a second-step merger without the need for a stockholder vote under Delaware law. The companies expect the transaction to close in the first quarter of 2015.

Merck buyout!!!

$68 gap had to be filled as previously stated. Should be up from here...

Looks like 86 plus might be in order based on so many purchases

Looks like heading to 86 after correction

Closing Fridays gap around $68. Looking for re entry down there.

$80 pre market high nice

Coverage initiated by Gabelli & Co. = Buy

Love it! Wondering where PPS heads to from here? Thoughts?

Approved!

Approval soon

Isnt anybody interested in CBST ?

Is 70 dollars too high a price for this company?

11:07AM Cubist Pharma submits Clinical Trial Application to initiate first-in-human study of CB-618-A beta-lactamase inhibitor discovered to combat antibiotic resistance (CBST) 68.80 -1.18 :

Co announced that it submitted a Clinical Trial Application (CTA) to the Dutch Competent Authority and Ethics Committee to initiate a first-in-human study of CB-618 in the Netherlands. Discovered by Cubist, CB-618 is a novel, broad-spectrum beta-lactamase inhibitor (BLI) investigational compound. Based on in vitro studies, CB-618 has been shown to increase the spectrum of activity of certain beta-lactam antibiotics. (Beta-lactamases are enzymes produced by some bacteria that provide resistance to certain beta-lactam antibiotics.)
If approved by the Dutch Competent Authority and Ethics Committee, co plans to conduct the proposed initial study during the first half of 2014. The purpose of the proposed study will be to evaluate the safety, tolerability and pharmacokinetics of CB-618 administered as single and multiple doses. The overall goal of the CB-618 development program is to enhance the spectrum of activity of beta-lactam antibiotics against resistant pathogens. CB-618 is part of a platform research approach by Cubist to identify new BLIs, which could potentially restore and expand the clinical utility of certain existing antibiotics. CB-618 is a product of research and development efforts at Cubist to combat multidrug resistance in Gram-negative pathogens.

Acquisition of Trius Therapeutics -call transcript -

read here
http://www.earningsimpact.com/Transcript/82627/CBST/Cubist-Pharmaceuticals-Inc---Cubist-Pharmaceuticals-to-Acquire-Trius-Therapeutics

8:27AM On The Wires (WIRES) : Cubist Pharmaceuticals (CBST) announced the initiation of its Phase 3 studies evaluating the efficacy and safety of CB-315 in patients with Clostridium difficile-associated diarrhea, with enrollment of a patient in the first of two planned identical global trials.

9:05AM Cubist Pharma unveils Five-Year strategic goals (CBST) 41.35 : Co announces five-year strategic aspirations at its Investor Da. In summary, by year-end 2017, co expects to: (-) Grow global revenue to $2 bln annually; (-) Have four product candidates in late-stage clinical trials; (-) Generate $700 mln in non-GAAP annual adjusted operating income; and (-) Continue to strengthen and develop the co's highly differentiated culture.

<<< $CBST Links! >>> ~ MAC's Quick DD Links without the charts.




PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/CBST


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/CBST/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/CBST/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/CBST/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/CBST/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/CBST/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/CBST/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/CBST/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/CBST/research


Google Finance Summary ~ http://www.google.com/finance?q=CBST
Google Finance News ~ http://www.google.com/finance/company_news?q=CBST
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=CBST
Google Finance Financials ~ http://www.google.com/finance?q=CBST&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=CBST
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=CBST&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=CBST+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=CBST+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=CBST+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=CBST
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=CBST+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=CBST+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/CBST
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/CBST
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=CBST+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=CBST+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=CBST+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=CBST+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=CBST+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=CBST+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=CBST+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=CBST+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=CBST+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=CBST+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=CBST+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=CBST&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=CBST
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=CBST
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=CBST
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=CBST
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=CBST
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=CBST&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=CBST&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/CBST?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/CBST
Barchart Options Quotes ~ http://barchart.com/options/stocks/CBST
Barchart Technical Chart ~ http://barchart.com/charts/stocks/CBST&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/CBST&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/CBST
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=CBST
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/CBST
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/CBST
Barchart News Headlines ~ http://barchart.com/news/stocks/CBST
Barchart Profile ~ http://barchart.com/profile//CBST
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=CBST&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=CBST&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=CBST&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=CBST&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/CBST/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/CBST/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/CBST/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/CBST/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/CBST
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/CBST/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/CBST/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/CBST/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/CBST/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/CBST/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/CBST/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=CBST&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=CBST


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=CBST


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=CBST&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=CBST
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=CBST


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=CBST&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=CBST.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=CBST®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/CBST
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/CBST/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/CBST/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/CBST/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=CBST&selected=CBST
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=CBST&selected=CBST
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/CBST/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/CBST/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/CBST/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/CBST/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/CBST/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/CBST/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/CBST/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/CBST/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/CBST/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/CBST/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/CBST/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/CBST/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/CBST/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/CBST/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=CBST&selected=CBST
NASDAQ Financials ~ http://www.nasdaq.com/symbol/CBST/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/CBST/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/CBST/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/CBST/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/CBST/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/CBST/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/CBST/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/CBST/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/CBST.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/CBST/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/CBST/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/CBST/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/CBST/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/CBST/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/CBST/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=CBST


YCharts ~ http://ycharts.com/companies/CBST
YCharts Performance ~ http://ycharts.com/companies/CBST/performance
YCharts Dashboard ~ http://ycharts.com/companies/CBST/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=CBST&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=CBST&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=CBST&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=CBST


Zacks Quote ~ http://www.zacks.com/stock/quote/CBST
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=CBST
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=CBST


Knobias ~ http://knobias.10kwizard.com/files.php?sym=CBST


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=CBST


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/CBST/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=CBST&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=CBST®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=CBST®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=CBST®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=CBST®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=CBST®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=CBST


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=CBST


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=CBST&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=CBST&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=CBST
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=CBST&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=CBST


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=CBST


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=CBST


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=CBST

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CBST
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=CBST

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=CBST

Investorpoint ~ http://www.investorpoint.com/ enter "CBST" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "CBST" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=CBST

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=CBST

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=CBST

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=CBST

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=CBST

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "CBST" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=CBST&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=CBST
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=CBST
Check those searches for recent CBST mentions. If CBST is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS



MACDlinks

~ Wednesday! $CBST ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $CBST ~ Earnings expected on Wednesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=CBST&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=CBST&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=CBST
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CBST#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CBST+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CBST
Finviz: http://finviz.com/quote.ashx?t=CBST
~ BusyStock: http://busystock.com/i.php?s=CBST&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=CBST >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Cubist Pharma CBST Oppenheimer Outperform $45 » $49

Read more: http://www.briefing.com/investor/calendars/upgrades-downgrades/#ixzz1r4cMt5O6

Cubist up after deal with TEVA to delay generic for 6 months!

Cubist Pharma CBST Wedbush Neutral » Outperform $25 » $32

Read more: http://www.briefing.com/Investor/Public/Calendars/UpgradesDowngrades.htm#ixzz1IeyCMT00

Cubist Pharma CBST Robert W. Baird Neutral » Outperform $22 » $35

Read more: http://www.briefing.com/Investor/Public/Calendars/UpgradesDowngrades.htm#ixzz1IeyPwRsq

Killing the Superbug: “Owning this stock is like holding a winning lottery ticket” (Skousen)
By StockGumshoe · November 15, 2010
http://stockgumshoe.com/2010/11/killing-the-superbug-owning-this-stock-is-like-holding-a-winning-lottery-ticket-skousen.html


kiwi

Cubist Pharmaceuticals(CBST_), however, was lower, trading down 3% to $24.25 on volume of more than 40,000, after releasing mixed third-quarter results.

The Lexington, Mass.-based biotech posted a profit of $31.2 million, or 50 cents a share, well head of the average analysts' view of 41 cents a share, but sales of $162.1 million were below the consensus of $166.4 million and represented a sequential decline from the company's second-quarter total of $168.5 million.

Cubist also tightened its revenue outlook for the full year, forecasting a range of $645 million to $650 million compared to its prior projection for revenue of between $627 million and $652 million, which it provided in April.

--Written by Michael Baron in New York.

September 12-15
Infectious-disease experts will be congregating in Boston for the International Conference of Antimicrobial Agents and Chemotherapy annual meeting. Investors of Cubist Pharmaceuticals (CBST) should be watching out for further data on CXA-101, a drug the company acquired last year. A glimpse of top-line results for the treatment of complicated urinary tract infections was released in June, but the company will be expanding on what looks like positive results. This is important to Cubist’s CXA-201 program, which is a combination of CXA-101 and another agent. The company has recently begun a mid-stage study for CXA-201.

http://www.minyanville.com/businessmarkets/articles/biotech-pharmaceuticals-obesity-diabetes-advisory-committee/9/1/2010/id/29903?camp=syndication&medium=portals&from=yahoo

CBST Q1 total net revenue up 19% vs Q1 09! AH press release also. CBST attributes the increase to CUBACIN. As I was saying in an earlier post, this could be a game changer IMHO this year. Will be interesting to see AH/PM trading. GL.

Cubist (CBST) Proprietary Antibiotics Netting $500 Million Annually And Is Forecasted To Grow, According To Industry Analyst

On Tuesday April 6, 2010, 2:13 pm EDT
67 WALL STREET, New York - April 6, 2010 - The Wall Street Transcript has just published its Biotechnology & Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This Special Feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Clinical, Financial & Regulatory Risks To Drug Development - Easing Capital Markets - Managing Inherent Volatility - FDA Approval Process - Small- & Mid-Cap M&A Rally - Basket Investment Approach - Impact Of Health Care Reform - Therapeutic Cardiovascular Plays - Investable Trend In Antibody Technology

Companies include: Genentech/Roche (RHHBY); Medivation (MDVN); Seattle Genetics (SGEN); AEterna Zentaris (AEZS); Abbott (ABT); Alexion (ALXN); Amgen (AMGN); Antares Pharmaceuticals (AIS); Ardea (RDEA); Astellas (4503); AstraZeneca (AZN); Auxilium (AUXL); Biogen (BIIB); CardioGenics (CHNG); Celera (CRA); Celgene (CELG); Celldex (CLDX); Corcept (CORT); and many more.

In the following brief excerpt from this Biotech and Pharmaceutical Special Report, industry experts discuss the outlook for the sector for investors.

Dr. Jason Kantor, Ph.D., joined RBC Capital Markets in 2005 as a Managing Director and Senior Biotechnology Equity Research Analyst. In 2004 Fortune magazine ranked Dr. Kantor as an "All-Star Analyst," and The Wall Street Journal ranked him second in its "Best on the Street" survey. Dr. Kantor received his B.A. cum laude in biology from the University of California, San Diego, and his Ph.D. in cell and developmental biology from Harvard University.

TWST: You mentioned the small- and mid-cap M And A rally. Would you talk about that for a minute?

Dr. Kantor: What I mean by that is in 2009 we saw Medarex and Genentech (DNA) taken out; we've already seen OSI Pharmaceuticals (OSIP) in play in the past weeks, and we've seen Facet (FACT), which was originally a target for Biogen (BIIB), ultimately getting taken out by Abbott (ABT) at a significant premium to where the Biogen deal was proposed. What we are seeing is a number of small- to mid-cap companies and, in some cases, large companies that are the targets of acquisition. Whenever that's the case and whenever you see companies paying 40%, 50%, 60% or more premium, you begin to see the other companies with similar profiles reflecting increased valuation.

TWST: Tell us about Pharmacyclics. What is your view on that company?

Dr. Kantor: Pharmacyclics (PCYC) is kind of a comeback story. It had been left for dead for a long time and it's really a remake. What I mean by that is its lead program, several years back, failed at the FDA. The company had acquired some preclinical early-stage projects from Celera (CRA) and has been diligently moving those forward. And it was not until late in 2009, at the American Society of Hematology meeting, where we saw the first clinical data for two of their drugs. The data in two different hard-to-treat lymphoma studies for two different drugs was actually quite impressive, and essentially put the company and the stock back on people's radar screen. And you can see the stock performance has been quite remarkable over the period from fall 2009 to today.

TWST: You mentioned OSI Pharma. Why is that company getting so much attention right now?

Dr. Kantor: There was an unsolicited hostile bid by Astellas (4503) to acquire the company for $52 a share, which was a significant premium to where the stock closed in the high $30s prior to that bid. That's the reason that OSI is in the news today. And the question is whether or not there will be another company bidding higher, or whether or not Astellas will need to raise their bid. Obviously with the stock trading in the high $50s, the overwhelming sentiment of investors is that OSI will get taken out at a higher price than $52 proposed in the unsolicited bid.

TWST: What about Celgene? What's happening with them?

Dr. Kantor: We highlighted Celgene (CELG) as our best idea, big-cap name for 2010. It is one of the top-growth stocks in biotech. It has a high p/e multiple, so it's certainly not without risk. But what's driving it here is the expansion globally of its multiple myeloma franchise and specifically REVLIMID. And what I like about it and what other folks like about it is the longevity of that growth curve. What I mean by that is there are significant new markets both geographically as well as in new disease indications for REVLIMID to enter over the next several years, such that we have good visibility on long-term, double-digit top-line growth. We also have very high margins in Celgene and in fact improving margins with product mix and geographic mix.

TWST: What about ImmunoGen?

Dr. Kantor: ImmunoGen (IMGN) is one of the few pure-play antibody technology companies, and this has been one of the very fruitful areas of M And A and deal-making that we've seen. For example, Genentech and Medarex, both antibody companies, Facet is another antibody company, and there are actually only a handful of remaining pure-play antibody companies. There is also a technology platform that's becoming very highly validated, called antibody-drug conjugation. This technology space is essentially controlled by an even smaller group of companies, including ImmunoGen and another one that I cover, Seattle Genetics (SGEN). There is scarcity value, that's one of the reasons we like ImmunoGen. The other reason of course is their lead program with Genentech/Roche (RHHBY) called T-DM1, which is a new drug for the treatment of breast cancer that has had some very exciting data and for which we expect Roche will file an NDA in the first half of 2010.

TWST: Who are your top picks right now and why?

Dr. Kantor: Our 2010 pick on the large-cap side is Celgene and on the small- to mid-cap side is Seattle Genetics, another pure-play antibody company with a deep pipeline of proprietary and partnered antibodies. And then I would add to that list, if you have a slightly longer time horizon, Cubist (CBST), which has proprietary antibiotics, which they sell directly with over $500 million in annual sales and growing. And we view this as the value play based on its low price-to-sales ratio.

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This Special Issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673

http://finance.yahoo.com/news/Cubist-CBST-Proprietary-twst-1314602260.html?x=0&.v=1

I sold out of CBST back in Feb, still been watching it. I see we still don't have a MOD on this one. Will have to update my DD on CBST, but looks like it broke its 2009 high and should set it up to test the 2008 high of $28.74 on the next move....

surf

Surf...you still here? Interesting developements taking place with the new C-Diff tx candidate. Great potential if it pans out. I have first hand experience with C-Diff infections in the acute clinical settings and see increasing resistance to traditional therapies currently inplace. Holding LONG with this one. Also of note, some of my infectous disease specialists are transitioning to Cubacin which has shown bactericidal properties (vs bacteriostatic properties with other antibiotics) regaurding MRSA skin infections. If our tx guidelines change officially at the hospitals nationally, this will be HUGE for CBST IMHO. MRSA is rapidly becoming a pandemic, new tx guidelines for hospitalized patients that include cubicin will significantly impact shareholders positively in the near future. GLTA !

4:04PM Cubist Pharma misses by $0.03, reports revs in-line (CBST) 20.57 -0.32 : Reports Q4 (Dec) earnings of $0.38 per share, $0.03 worse than the First Call consensus of $0.41; revenues rose 27.1% year/year to $166.7 mln vs the $165.6 mln consensus. CBST reports Cubicin drug sales of $147.8 mln vs. $129.6 mln First Call Consensus. "As we begin 2010, Cubist continues to build on the foundation we've created with the development and commercial success of CUBICIN. Our acute care focus and our disciplined approach to building a pipeline of differentiated therapies addressing areas of high unmet medical need puts Cubist in a strong position during times of continued uncertainty in the economy overall and in the healthcare marketplace in particular."

Going to bust $20 today IMO

Holding it's own with a down market, looking to break $20 in next week...imho, GLTA here

7:08AM Cubist Pharma announces FY09 total net revenue of $562.1 mln vs $559.5 consensus (CBST) 18.78 : Co announces 4Q09 U.S. CUBICIN net product revenues of $147.8 mln (unaudited); this represents an increase of 23%, or $27.7 mln, from 4Q08 U.S. CUBICIN net product revenues. Co announces FY09 U.S. CUBICIN net product revenues of $524.0 mln (unaudited); this represents an increase of 26%, or $109.3 mln, from FY08 U.S. CUBICIN net product revenues. Co's share of FY09 international net product revenues was $13.8 mln (unaudited); this represents an increase of 86%, or $6.4 mln, from FY08. Service revenues for FY09 were $22.5 mln (unaudited), an increase of 139%, or $13.1 mln, from 2008 and relate to Cubist's promotion and other activities in the U.S. with respect to MERREM I.V. Total net revenue for FY09 was $562.1 mln vs $559.5 mln consensus.

Outstanding vs Float
57,765,668 57,589,851

whats up with these #'s, why are they so close?

ditto ..

--
4kids
all jmo

Jumped a dollar as soon as Najarian pr'd the unusual option activity occurring with us. This is going to get interesting. Maybe a buyout is coming our way. GLTY

needham analyst
gave a plug today
on cnbc for cubist

1 of 4 he highlighted

--
4kids
all jmo

moving up from here - keep your eye on the ball

Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
6:30a ET July 2, 2008 (Business Wire)
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has signed an exclusive agreement with AstraZeneca (NYSE: AZN) to promote and provide other support in the United States for MERREM(R) I.V. (meropenem for injection), an established broad spectrum (carbapenem class) I.V. antibiotic. Cubist will promote and support MERREM I.V. using its existing U.S. acute care sales and medical affairs organizations. AstraZeneca will continue to provide marketing and commercial support for MERREM I.V. The agreement, effective July 1, 2008, establishes a baseline of $20 million annual revenue to Cubist that will be adjusted based on actual MERREM I.V. sales. Other terms of the agreement, including the performance incentives, are confidential.

Cubist Executive Vice President and Chief Operating Officer Robert J. Perez said of the agreement: "As a broad spectrum antibiotic, MERREM I.V. is an excellent fit with our Gram positive therapy, CUBICIN, which has experienced the most successful I.V. antibiotic launch in U.S. history in dollar terms. The agreement with AstraZeneca immediately leverages the Cubist sales and medical affairs teams that have contributed to making CUBICIN so successful in the U.S."

According to Marion McCourt, Vice-President, GI & Infection, AstraZeneca, "This agreement will allow AstraZeneca to maximize the value of MERREM I.V. while continuing to bring this important product to health care providers and patients. The Cubist sales force is well recognized by infectious disease specialists and is highly respected by its customers."

Indications and Important Safety Information

MERREM I.V. is indicated as single-agent therapy for the treatment of complicated appendicitis and peritonitis, complicated skin and skin structure infections, and pediatric (greater than or equal to 3 months of age) bacterial meningitis, when caused by susceptible isolates of the indicated pathogens.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of MERREM I.V. and other antibacterial drugs, MERREM I.V. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

MERREM I.V. is contraindicated in patients with known hypersensitivity to any component of the product, or to other drugs in the same class, or in patients who have demonstrated anaphylactic reactions to beta-lactams.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens.

There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam.

Seizures and other CNS adverse experiences have been reported during treatment with MERREM I.V.

Carbapenems, including meropenem, may reduce serum valproic acid concentrations to subtherapeutic levels, resulting in loss of seizure control. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy.

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including MERREM I.V., and may range in severity from mild diarrhea to fatal colitis. CDAD must be considered in all patients who present with diarrhea following antibiotic use.

The most common adverse events reported across clinical trials with MERREM I.V. were diarrhea, nausea/vomiting, headache, constipation, anemia, and pain. These events occurred in 3% to 8% of patients.

Full prescribing information can be found at http://www1.astrazeneca-us.com/pi/MerremIV.pdf

Drug resistant infections rise:

http://www.ajc.com/health/content/health/stories/2008/05/03/mrsa_0504.html?cxntlid=homepage_tab_newstab